Validation of a stability indicating reversed phase LC method for the determination of fluticasone propionate in pharmaceutical formulations

Journal of Liquid Chromatography and Related Technologies

Volumn 31, Issue 14, 2008, Pages 2113-2127

  Sangoi, Maximiliano Da Silva ^a   Nogueira, Daniele Rubert ^a   Da Silva, Lucélia Magalhães ^a   Leal, Diogo Paim ^a   Dalmora, Sérgio Luiz ^a  

^a FEDERAL UNIVERSITY OF SANTA MARIA   (Brazil)

Author keywords

Fluticasone propionate; Pharmaceutical formulations; Reversed phase liquid chromatography; Stability indicating method; Validation

Indexed keywords

CHROMATOGRAPHIC ANALYSIS; CONTROL THEORY; CUSTOMER SATISFACTION; DRUG PRODUCTS; HIGH PRESSURE LIQUID CHROMATOGRAPHY; LIQUID CHROMATOGRAPHY; LIQUID PHASE EPITAXY; MILITARY DATA PROCESSING; PESTICIDES; PHASE STABILITY; PROBLEM SOLVING; QUALITY ASSURANCE; QUALITY FUNCTION DEPLOYMENT; ROBUST CONTROL; SEPARATION; SPRAYING; SULFATE MINERALS; SYSTEM STABILITY; TOTAL QUALITY MANAGEMENT;

APPLIED (CO); CHROMATOGRAPHIC SEPARATIONS; LC METHOD; LIMITS OF DETECTION AND QUANTITATION; METHOD VALIDATIONS; MOBILE PHASE; PHARMACEUTICAL FORMULATIONS; PHOSPHATE BUFFER (PBS); PHOTODIODE ARRAY (PDA); RETENTION TIME (RT); REVERSED PHASE (RP); REVERSED-PHASE LIQUID CHROMATOGRAPHY (RPLC);

QUALITY CONTROL;

FLUTICASONE PROPIONATE; NOSE SPRAY;

ACCURACY; ARTICLE; DRUG FORMULATION; DRUG STABILITY; DRUG STRUCTURE; REVERSED PHASE LIQUID CHROMATOGRAPHY; VALIDATION PROCESS;

EID: 46849087556     PISSN: 10826076     EISSN: 1520572X     Source Type: Journal    
DOI: 10.1080/10826070802225395     Document Type: Article

References (18)

1. Johnson, M. Development of fluticasone propionate and comparison with other inhaled corticosteroids. J. Allergy Clin. Immunol. 1998, 101, S434-S439.
2. Szefler, S.J. Pharmacokinetics of intranasal corticosteroids. J. Allergy Clin. Immunol. 2001, 108, S26-S31.
3. Hebert, A.A.; Friedlander, S.F.; Allen, D.B. Topical fluticasone propionate lotion does not cause HPA axis supression. J. Pediatr. 2006, 149, 378-382.
4. Fuller, R.; Johnson, M.; Bye, A. Fluticasone propionate - an update on preclinical and clinical experience. Respir. Med. 1995, 89, 3-18.
5. Dahl, R.; Nielsen, L.P.; Kips, J.; Foresi, A.; van Cauwenberge, P.; Tudoric, N.; Howarth, P.; Richards, D.H.; Williams, M.; Pauwels, R. Intranasal and inhaled fluticasone propionate for pollen-induced rhinitis and asthma. Allergy 2005, 60, 875-881.
6. Prenner, B.M.; Schenkel, E. Allergic rhinitis: treatment based on patient profiles. Am. J. Med. 2006, 119, 230-237.
7. Fowler, P.D.; Gazis, A.G.; Page, S.R.; Jones, N.S. A Randomized double-blind study to compare the effects of nasal fluticasone and betamethasone on the hypothalamo-pituitary-adrenal axis and bone turnover in patients with nasal polyposis. Clin. Otolaryngol. 2002, 27, 489-493.
8. Li, Y.N.; Tattam, B.N.; Brown, K.F.; Seale, J.P. A sensitive method for the quantification of fluticasone propionate in human plasma by high-performance liquid chromatography/atmospheric pressure chemical ionisation mass spectrometry. J. Pharm. Biomed. Anal. 1997, 16, 447-452.
9. Krishnaswami, S.; Möllmann H., Derendorf, H.; Hochhaus, G. A sensitive LC-MS/MS method for the quantification of fluticasone propionate in human plasma. J. Pharm. Biomed. Anal. 2000, 22, 123-129.
10. Laugher, L.; Noctor, T.G.; Barrow, A.; Oxford, J.M.; Phillips, T. An improved method for the determination of fluticasone propionate in human plasma. J. Pharm. Biomed. Anal. 1999, 21, 749-758.
11. Callejas, S.L.; Biddlecombe, R.A.; Jones, A.E.; Joyce, K.B.; Pereira, A.I.; Pleasance, S. Determination of the glucocorticoid fluticasone propionate in plasma by automated solid-phase extraction and liquid chromatography-tandem mass spectrometry. J. Chromatogr. B 1998, 718, 243-250.
12. Taylor, R.L.; Grebe, S.K.; Singh, R.J. Quantitative, highly sensitive liquid chromatography-tandem mass spectrometry method for detection of synthetic corticosteroids. Clin. Chem. 2004, 50, 2345-2352.
13. Murname, D.; Martin, G.P.; Marriot, C.J. Validation of a reverse-phase high performance liquid chromatographic method for concurrent assay of a weak base (Salmeterol Xinafoate) and a pharmacologically active steroid (Fluticasone Propionate). Pharm. Biomed. Anal. 2006, 40, 1149-1154.
14. Bernal, J.L.; Nozal, M.J.; Martín, M.T.; Diez-Masa, J.C.; Cifuentes, A. Quantitation of active ingredients and excipients in nasal sprays by high-performance liquid chromatography, capillary electrophoresis and UV spectroscopy. J. Chromatogr. A 1998, 823, 423-431.
15. International Conference on Harmonization (ICH) of Technical Requirements for the Registration of Pharmaceutical for Human Use, Validation of Analytical Procedures: Text and Methodology Q2(R1), November 2005; 1-13.
16. International Conference on Harmonization (ICH) of Technical Requirements for the Registration of Pharmaceutical for Human Use, Stability Testing of New Drugs Substance and Products Q1A(R2), February 2003; 1-18.
17. Alsante, K.M.; Ando, A.; Brown, R.; Ensing, J.; Hatajik, T.D.; Kong, W.; Tsuda, Y. The role of degradant profiling in active pharmaceutical ingredients and drug products. Adv. Drug Deliv. Rev. 2007, 59, 29-37.
18. Ermer, J.; Ploss, H.J. Validation in pharmaceutical analysis part II: central importance of precision to establish acceptance criteria and for verifying and improving the quality of analytical data. J. Pharm. Biomed. Anal. 2005, 37, 859-870.